-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Benzinga·11/06/2024 10:08:23
Listen to the news
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $7 price target.